Market Cap | 2.53B | P/E | - | EPS this Y | -2.50% | Ern Qtrly Grth | - |
Income | -374.93M | Forward P/E | -8.23 | EPS next Y | -10.50% | 50D Avg Chg | 31.00% |
Sales | 49.63M | PEG | -0.37 | EPS past 5Y | - | 200D Avg Chg | 55.00% |
Dividend | N/A | Price/Book | 5.88 | EPS next 5Y | 12.00% | 52W High Chg | -21.00% |
Recommedations | 2.70 | Quick Ratio | 5.54 | Shares Outstanding | 275.07M | 52W Low Chg | 190.00% |
Insider Own | 4.55% | ROA | -34.35% | Shares Float | 245.45M | Beta | 0.81 |
Inst Own | 87.46% | ROE | -71.18% | Shares Shorted/Prior | 59.16M/54.15M | Price | 13.17 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 5,772,806 | Target Price | 9.44 |
Oper. Margin | -697.39% | Earnings Date | Nov 7 | Volume | 4,541,377 | Change | -4.67% |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Larson Tina Marriott | President and COO President and COO | Jan 25 | Sell | 10.35 | 8,000 | 82,800 | 414,548 | 01/29/24 |
Larson Tina Marriott | President and COO President and COO | Jan 25 | Option | 1.06 | 8,000 | 8,480 | 422,584 | 01/29/24 |
Borgeson Blake | Director Director | Jan 23 | Sell | 10.5756 | 20,054 | 212,083 | 7,324,364 | 01/25/24 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Jan 16 | Sell | 10.93 | 18,000 | 196,740 | 136,748 | 01/18/24 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Jan 16 | Option | 2.22 | 18,000 | 39,960 | 154,748 | 01/18/24 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Jan 16 | Sell | 10.35 | 50,000 | 517,500 | 981,014 | 01/18/24 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Jan 16 | Option | 2.22 | 75,000 | 166,500 | 1,006,014 | 01/18/24 |
Li Dean Y | Director Director | Jan 09 | Sell | 13.84 | 29,000 | 401,360 | 421,000 | 01/11/24 |
Borgeson Blake | Director Director | Jan 09 | Sell | 13.51 | 20,054 | 270,930 | 7,344,418 | 01/11/24 |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Jan 03 | Sell | 9.5 | 55,853 | 530,604 | 01/05/24 | |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Jan 03 | Option | 2.48 | 31,250 | 77,500 | 822,578 | 01/05/24 |
Larson Tina Marriott | President and COO President and COO | Dec 28 | Option | 1.06 | 8,000 | 8,480 | 422,548 | 01/02/24 |
Larson Tina Marriott | President and COO President and COO | Dec 28 | Sell | 10.58 | 8,000 | 84,640 | 414,548 | 01/02/24 |
Borgeson Blake | Director Director | Dec 26 | Sell | 10.6285 | 20,054 | 213,144 | 7,364,472 | 12/28/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Dec 15 | Sell | 9.6 | 18,000 | 172,800 | 136,748 | 12/19/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Dec 15 | Option | 2.22 | 18,000 | 39,960 | 154,748 | 12/19/23 |
Dar Zavain | Director Director | Dec 14 | Sell | 9.00 | 20,141 | 181,269 | 53,823 | 12/18/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Dec 12 | Sell | 7.49 | 50,000 | 374,500 | 956,014 | 12/14/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Dec 12 | Option | 2.22 | 75,000 | 166,500 | 981,014 | 12/14/23 |
Borgeson Blake | Director Director | Dec 12 | Sell | 7.3987 | 11,447 | 84,693 | 7,384,526 | 12/14/23 |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Dec 06 | Sell | 7.49 | 59,829 | 448,119 | 791,328 | 12/08/23 |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Dec 06 | Option | 2.48 | 31,250 | 77,500 | 851,157 | 12/08/23 |
Borgeson Blake | Director Director | Nov 28 | Sell | 6.7195 | 11,447 | 76,918 | 7,395,973 | 11/30/23 |
Larson Tina Marriott | President and COO President and COO | Nov 15 | Sell | 6.76 | 3,000 | 20,280 | 413,404 | 11/17/23 |
Larson Tina Marriott | President and COO President and COO | Nov 15 | Option | 1.06 | 3,000 | 3,180 | 416,404 | 11/17/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Nov 15 | Sell | 6.51 | 18,000 | 117,180 | 140,351 | 11/17/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Nov 15 | Option | 2.22 | 18,000 | 39,960 | 158,351 | 11/17/23 |
Borgeson Blake | Director Director | Nov 14 | Sell | 6.3197 | 8,885 | 56,151 | 7,407,420 | 11/16/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Nov 14 | Sell | 7.06 | 50,000 | 353,000 | 938,186 | 11/16/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Nov 14 | Option | 2.22 | 75,000 | 166,500 | 963,186 | 11/16/23 |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Nov 01 | Sell | 5.15 | 62,177 | 320,212 | 11/03/23 | |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Nov 01 | Option | 2.48 | 31,250 | 77,500 | 873,997 | 11/03/23 |
Borgeson Blake | Director Director | Oct 31 | Sell | 5.2745 | 8,885 | 46,864 | 7,416,305 | 11/02/23 |
Larson Tina Marriott | President and COO President and COO | Oct 26 | Sell | 5.63 | 3,000 | 16,890 | 418,782 | 10/30/23 |
Larson Tina Marriott | President and COO President and COO | Oct 26 | Option | 1.06 | 3,000 | 3,180 | 421,782 | 10/30/23 |
Borgeson Blake | Director Director | Oct 17 | Sell | 6.5822 | 8,885 | 58,483 | 7,425,190 | 10/19/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Oct 16 | Sell | 6.3 | 18,000 | 113,400 | 140,351 | 10/18/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Oct 16 | Option | 2.22 | 18,000 | 39,960 | 158,351 | 10/18/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Oct 10 | Sell | 6.96 | 50,000 | 348,000 | 913,186 | 10/12/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Oct 10 | Option | 2.22 | 75,000 | 166,500 | 938,186 | 10/12/23 |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Oct 04 | Sell | 7.21 | 59,794 | 431,115 | 842,747 | 10/06/23 |
Gibson Christopher | Chief Executive Offi.. Chief Executive Officer | Oct 04 | Option | 2.48 | 31,250 | 77,500 | 902,541 | 10/06/23 |
Borgeson Blake | Director Director | Oct 03 | Sell | 7.2907 | 8,885 | 64,778 | 7,434,075 | 10/05/23 |
Larson Tina Marriott | President and COO President and COO | Sep 28 | Sell | 7.72 | 3,000 | 23,160 | 418,782 | 10/02/23 |
Larson Tina Marriott | President and COO President and COO | Sep 28 | Option | 1.06 | 3,000 | 3,180 | 421,782 | 10/02/23 |
Borgeson Blake | Director Director | Sep 19 | Sell | 8.3599 | 8,885 | 74,278 | 7,442,960 | 09/21/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Sep 15 | Sell | 8.66 | 18,000 | 155,880 | 140,351 | 09/19/23 |
Virani Shafique | Chief Business Offic.. Chief Business Officer | Sep 15 | Option | 2.22 | 18,000 | 39,960 | 158,351 | 09/19/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Sep 12 | Sell | 8.56 | 50,000 | 428,000 | 888,186 | 09/14/23 |
Secora Michael | Chief Financial Offi.. Chief Financial Officer | Sep 12 | Option | 2.22 | 75,000 | 166,500 | 913,186 | 09/14/23 |